A case of disseminated and fulminant plasmacytomas that developed during bortezomib treatment

Case Reports in Oncology

Volumn 4, Issue 1, 2011, Pages 101-105

  Bae, Soo Young ^a   Ahn, Jae Sook ^a   Yang, Deok Hwan ^a   Kim, Yeo Kyeoung ^a   Min, Jung Joon ^a   Song, Ho Chun ^a   Bom, Hee Seung ^a   Jeong, Yong Yeon ^a   Kim, Hyeoung Joon ^a   Lee, Je Jung ^a,b  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Bortezomib; Fulminant plasmacytoma; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; CALCIUM; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HEMOGLOBIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; MELPHALAN; PREDNISOLONE; SERUM ALBUMIN; THALIDOMIDE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BLOATING; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FULMINANT DISSEMINATED PLASMACYTOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; MALE; MOUTH DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMACYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 79957608282     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000324920     Document Type: Article

References (13)

1. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG: The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;23:2222-2232.
2. Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Blade J, Montserrat E: Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006;76:405-408.
3. Dytfeld D, Matuszak M, Lewandowski K, Komarnicki M: Bortezomib in combination with thalidomide and dexamethasone - a successful treatment regimen in refractory extramedullary multiple myeloma. Ann Hematol 2008;87:253-254. (Pubitemid 351167232)
4. Fukushima T, Nakamura T, Miki M, Sakai T, Iwao H, Nakajima A, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Hirose Y, Umehara H: Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas. Anticancer Res 2010;30:3791-3794.
5. Varettoni M, Mangiacavalli S, Zappasodi P, Pica GM, Lazzarino M, Corso A: Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas. Leuk Res 2008;32:839-841.
6. Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, Lee JL, Ahn JS, Moon JH, Shin HJ, Choi YJ, Lee WS, Kim HJ, Lee JJ: Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk 2010;10:62-67.
7. Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ: Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 2010;89:475-482.
8. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 2004;351:1860-1873.
9. Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wisloff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerstrom J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL: Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006;91:1228-1233. (Pubitemid 44408433)
10. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. (Pubitemid 36741588)
11. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-3560. (Pubitemid 350159621)
12. Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH: Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Ann Hematol 2010;89:905-912.
13. Ali R, Ozkalemkas F, Ozkan A, Ozkocaman V, Ozcelik T, Ozan U, Kurt M, Tunali A: Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon. Leuk Res 2007;31:1153-1155.